Summary
Biotechnology is a rapidly developing area of drug development which has great growth potential. Development of genetically engineered drugs is very expensive and as these products become available the impact on healthcare costs could be vast. The cost-benefit ratio of biotechnology products needs to be established, but few relevant pharmacoeconomic studies are available. Issues in pharmacoeconomic analysis of genetically engineered drugs can be exemplified by the data available for alteplase, epoetin and interferon α-2b.
One study concluded that thrombolysis with streptokinase rather than alteplase would substantially reduce the percentage of total hospital costs that were not reimbursed. However, differences in efficacy were not accounted for. Based on the superior efficacy of alteplase, a more extensive pharmacoeconomic analysis found that alteplase was more cost-effective than streptokinase when the agents were combined with aggressive reocclusion management. However, this conclusion may be altered by the finding of a more recent study that streptokinase may be at least as effective as alteplase.
Economic factors involved in epoetin treatment of anaemia associated with chronic renal disease have been studied thoroughly. However, cost-effectiveness or cost-benefit analysis was not attempted, and improvement in quality of life with epoetin therapy also needs to be considered, to facilitate cost-utility analysis.
Compared with chlorambucil, the use of interferon α-2b for hairy cell leukaemia resulted in significant direct and indirect cost savings, in a retrospective cost-benefit analysis. However, the validity of the results may be compromised by use of the Delphi approach (a panel of experts), rather than direct clinical trial data, to estimate disease severity and survival expectancy; and also by the comparison of treatments given in different time periods.
Similar content being viewed by others
References
Amadio J, Mueller J, Casey R. Benefit/cost ratios in public health. Illinois Department of Public Health, Southern Illinois University, Carbondale and Jackson County Health Department, August 1976
Bootman JL, McGhan WF. A perspective on the cost-benefit of drug therapy. Journal of Clinical Research Practice and Drug Regulatory Affairs 3: 53–69, 1985
Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics. Harvey Whitney Books, Cincinnati, 1991
Creagan ET. Malignant melanoma: cost and reimbursement issues. Seminars in Oncology 16 (Suppl. 1): 45–50, 1989
FDC Reports, pp. 1–2, January 1, 1990
Gilewski T, Vogelzang NJ. Cost-effectiveness and reimbursement issues in renal cell carcinoma. Seminars in Oncology 16 (Suppl. 1): 20–26, 1989
Green JA. Drug-use evaluation of thrombolytic agents: a challenge to pharmacists. American Journal of Hospital Pharmacy 54: 2192–2194, 1988
Green JA. Risks versus benefits: the alteplase experience. American Journal of Hospital Pharmacy 46 (Suppl. 2): S15–S19, 1989
Grimm AM, Flaharty KK, Hopkins LE, Mauskopf J, Besarab A et al. Economics of epoetin therapy. Clinical Pharmacy 8: 807–810, 1989
Health Care Financing Administration. National health expenditures, 1986–2000. Health Care Financial Review 8: 1–36, 1987
ISIS-3 Results. Presented at the American College of Cardiology Annual Meeting, Atlanta, Georgia, March 1991
Jones EH. Recombinant human erythropoietin. American Journal of Hospital Pharmacy 46 (Suppl. 2): S20–S23, 1989
Jordan NS, Kelly N. Hospital charges and reimbursement for alteplase and streptokinase. American Journal of Hospital Pharmacy 47: 296, 1990
Koeller JM. Biologic response modifiers: the interferon alfa experience. American Journal of Hospital Pharmacy 46 (Suppl. 2): S11–S15, 1989
Laffel GL, Fineberg HV, Braunwald E. A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. Journal of the American College of Cardiology 10: 79B–90B, 1987
Lundin AP. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Seminars in Nephrology 9 (Suppl. 1): 22–29, 1989
Lundin AP, Quinn RM, DeLano BG, Friedman EA. Subjective benefits of recombinant erythropoietin (r-HuEPO) in hemodialysis patients. Abstract. American Journal of Kidney Disease 13: 12, 1989
Office of Technology Assessment, US Congress. Commercial biotechnology: an international analysis. OTA-BA-218. US Government Printing Office, Washington, DC, January 1984
Ozer H, Golomb HM, Zimmerman H, Spiegel RJ. Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia. Journal of the National Cancer Institute 81: 594–602, 1989
Pharmaceutical Manufacturers Association. Biotechnology medicines in development. Pharmaceutical Manufacturers Association, Washington, DC, March 1990
Werner RG. Biobusiness in the pharmaceutical industry. Arzneimittel-Forschung 37: 1086–1093, 1987
Wittels EH, Hay JW, Gotton AM. Medical costs of coronary artery disease in the United States. American Journal of Cardiology 65: 432–440, 1990
Yee GC. Colony-stimulating factors and tomorrow’s pharmacy: why we must be ready. American Journal of Hospital Pharmacy 46 (Suppl. 2): S24–S29, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jones-Grizzle, A.J., Bootman, J.L. Pharmacoeconomics of Genetically Engineered Drugs. Pharmacoeconomics 1, 45–53 (1992). https://doi.org/10.2165/00019053-199201010-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199201010-00009